$1.08
+0.03 (+2.86%)
Open$1.07
Previous Close$1.05
Day High$1.10
Day Low$1.05
52W High$2.99
52W Low$0.50
Volume—
Avg Volume129.3K
Market Cap43.17M
P/E Ratio—
EPS$-0.68
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+925.0% upside
Current
$1.08
$1.08
Target
$11.07
$11.07
$6.75
$11.07 avg
$12.78
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 34.15M | 42.63M | 7.77M |
| Net Income | -75,587,845 | -84,908,962 | 1.80M |
| Profit Margin | -221.3% | -210.3% | 23.2% |
| EBITDA | -43,451,403 | -51,521,259 | 2.38M |
| Free Cash Flow | — | — | 1.78M |
| Rev Growth | -19.9% | -19.9% | +3.8% |
| Debt/Equity | 1.72 | 1.72 | 0.84 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |